World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 19 February 2015
Main ID:  NCT01642979
Date of registration: 14/07/2012
Prospective Registration: Yes
Primary sponsor: Institute of Hematology & Blood Diseases Hospital
Public title: Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria PNH-2012
Scientific title: Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
Date of first enrolment: July 2012
Target sample size: 120
Recruitment status: Active, not recruiting
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
Name:     yizhou zheng, doctor
Affiliation:  Institute of Hematology & Blood Diseases Hospital
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Clinical and biochemical signs of classic Paroxysmal Nocturnal Hemoglobinuria

2. Diagnosis confirmed by Ham's test or Flow cytometry Patients have any Flow cytometry

3. patient should complete levamisole study for at least half a year

Exclusion Criteria:

1. Active infection which requires antibiotic treatment

2. Pregnant or lactating women

3. Epilepsy and mental illness

4. Kidney and liver function abnormal

5. patient who terminate ealy from levamisole study

Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Anemia, Hemolytic
Aplastic Anemia,
Bone Marrow Failure
Hemoglobinuria, Paroxysmal
Paroxysmal Nocturnal Hemoglobinuria
Urination Disorders
Drug: cyclosporin A+Glucocorticoids
Drug: Glucocorticoids
Drug: Levamisole+cyclosporin A+Glucocorticoids
Primary Outcome(s)
Number of patients in each group in complete or partial remission [Time Frame: 6 months]
Secondary Outcome(s)
Side effects [Time Frame: 6 months]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history